BioCentury
ARTICLE | Clinical News

Virulizin: IMUTF began a Phase I/II trial

June 24, 1996 7:00 AM UTC

Imutec Corp. (IMUTF), Toronto, Ontario Product: Virulizin, bovine bile extract to activate macrophages Indication: Pancreatic cancer Status: IMUTF began a Phase I/II trial in 20 patients to assess tu...